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PD-L1 expression predicts longer disease free survival in high risk head
and neck cutaneous squamous cell carcinoma
Abstract
Programmed cell death (PD-1) and its ligand (PD-L1) inhibitors have shown clinical response in many
tumours. PD-L1 data are limited in head and neck cutaneous squamous cell carcinoma (HNcSCC) and no
clinical trials of PD-1/PD-L1 inhibitors are published. We performed PD-L1 immunohistochemistry on 74
cases of high risk HNcSCC with 38 matched metastases and evaluated clinicopathological associations,
prognostic significance and heterogeneity in matched metastases. We observed PD-L1 expression in >5% of
primary tumour cells in 29 cases (39.2%), primary tumour infiltrating lymphocytes (TILs) in 40 cases
(70.2%), metastatic tumour cells in 15 cases (39.5%), and metastatic TILs in 18 cases (47.4%). PD-L1
expression in >5% of primary tumour cells was associated with an inflammatory phenotype (p = 0.04), and in
primary TILs with clear margins (p = 0.05). PD-L1 expression in >5% of primary tumour cells (p = 0.01),
primary TILs (p = 0.001), and metastatic TILs (p = 0.02) was associated with improved disease free survival.
PD-L1 expression in >5% of tumour cells was heterogeneous between primary and metastatic tumours in 13
cases (34.2%). PD-L1 expression is common in HNcSCC supporting the rationale for a clinical trial of PD-1/
PD-L1 inhibitors. PD-L1 expression in tumour cells or TILs predicts longer disease free survival and
demonstrates temperospatial heterogeneity.
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Mean tumor  PD‐L1 0‐5%  15.0  0.54  16.4  0.26 
23 
 
thickness (mm)  PD‐L1 >5%  13.0  12.8 
Categorical variables  PD‐L1 staining percentage > 5% 
Tumor 
cells 
p  TILs  p 
Gender  Male 
Female 
37.5% 
50.0% 
0.45  62.5% 
50.0% 
0.45 
T category  T1/2 
T3/4 
43.9% 
23.5% 
0.13  61.4% 
58.8% 
0.85 
Node / Metastasis 
status 
Negative 
Positive 
40.0% 
38.5% 
0.89  65.7% 
56.4% 
0.41 
Tumor infiltrating 
lymphocyte 
Absent 
Present 
17.7% 
45.6% 
0.04  N/A 
70.2% 
N/A 
Margins  Clear 
Involved 
45.7% 
28.6% 
0.14  69.6% 
46.4% 
0.05* 
Differentiation  Well 
Moderate 
Poor 
20.0% 
42.6% 
36.4% 
0.59  100% 
61.7% 
50.0% 
0.12 
Perineural invasion  Absent 
Present 
48.7% 
29.7% 
0.10  70.3% 
51.4% 
0.10 
Lymphovascular 
invasion 
Absent 
Present 
37.7% 
46.2% 
0.57  60.7% 
61.5% 
0.95 
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Table 4 – Disease free survival and PD‐L1 expression in HNcSCC 
  Primaries  Metastases 
  Tumor cells 
(n=74) 
TILs (n=57)  Tumor cells 
(n=38) 
TILs (n=38) 
PD‐L1 staining 
percentage 
> 5% vs. 0‐5% 
P = 0.01* 
HR = 0.43 
CI = 0.23‐0.83 
See graph 1 
> 5% vs. 0‐5% 
P = 0.001* 
HR = 0.30 
CI = 0.15‐0.60 
See graph 2 
> 5% vs. 0‐5% 
P = 0.40 
HR = 1.45 
CI = 0.61‐3.43 
> 5% vs. 0‐5% 
P = 0.02* 
HR = 0.35 
CI = 0.14‐0.87 
See graph 3 
PD‐L1 staining 
intensity 
2/3+ vs. 0+ 
P = 0.09 
HR = 0.53 
CI = 0.25‐1.10 
2/3+ vs. 0+ 
P = 0.01* 
HR = 0.41 
CI = 0.20‐0.84 
2/3+ vs. 0+ 
P = 0.64 
HR = 1.25 
CI = 0.48‐3.24 
2/3+ vs. 0+ 
P = 0.04* 
HR = 0.35 
CI = 0.13‐0.95 
 
 
 
   
Table 5 – PD‐L1 expression in primary HNcSCC tumor cells and matched metastases (n=38) 
  PD‐L1 0‐5% in metastases  PD‐L1 > 5% in metastases 
PD‐L1 0‐5% in primaries  16 (42.1%)  8 (21.1%) 
PD‐L1 > 5% in primaries  5 (13.2%)  9 (23.4%) 
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